Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Moullier P, Snyder, RO. International efforts for recombinant adeno-associated viral vector reference standards. Mol. Ther. 16:1185-1188, 2008.
Potter M, et al. Manufacture and stability study of the recombinant adeno-associated virus serotype 2 vector reference standard. BioProcessing Journal 7:8-14, 2008.
Burger C. et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Molecular Therapy : 10(2):302-17, 2004 PubMed: 15294177
Flotte TR, e al. Utility of a recombinant adeno-associated viral vector reference standard. BioProcessing J. 1: 75, 2002.
Chadeuf G, et al. Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J. Gene Med. 2(4):260-268, 2000. PubMed: 10953917.
Grimm D, et al. Novel tools for production and purification of recombinant adeno-associated virus vectors. Human Gene Therapy 9: 2745-2760, 1998.
